Hematologic Malignancies Section News Today

Joseph G. Jurcic, MD, discusses the use of JAK inhibitors in the management of myelofibrosis.

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

/PRNewswire/ -- Bio Ascend, Vaniam Groups medical education company, this past weekend reconvened the inaugural class of its Academy of Next Wave of...

Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.

Nicole Lamanna, MD, discusses the challenges of resistance in patients with CLL, highlights treatment being developed for patients who progress on BTK inhibitor– or venetoclax-based regimens, and emphasizes the need for further enrollment onto clinical trials.

The FDA approval of the first CAR T-cell therapy for children and young adults with B-cell ALL changed the treatment paradigm for this disease.

The FDA approval of the first CAR T-cell therapy for children and young adults with B-cell ALL changed the treatment paradigm for this disease.